Core Concepts — BCHM614: Signal Transduction and Receptor Biology
Skipper’s conceptual goal: to understand how a molecular encounter at a receptor becomes a selective, amplified, time-dependent biological response—and how peptide chemistry can reshape that entire process.
1. What Signal Transduction Is Really About: Molecules Becoming Decisions
A pancreatic β-cell, a hypothalamic neuron, and a hepatocyte can encounter related peptide hormones yet make entirely different decisions. One releases insulin, another changes electrical activity, and another increases hepatic glucose output. The hormone does not contain a complete instruction manual for these outcomes. Rather, it perturbs a receptor embedded in a particular cellular system. The response emerges from the receptor’s conformational behavior, the available signaling proteins, cellular metabolism, spatial organization, and the history of previous stimulation.
Signal transduction is therefore the study of how cells interpret molecular information. Receptors recognize inputs; biochemical networks transform those inputs; effectors alter metabolism, secretion, movement, survival, or gene expression. A signaling pathway is not merely a sequence of arrows. It is a dynamic, energy-consuming system with gain, thresholds, delays, feedback, and memory. [Alberts et al., 2022]
This builds directly on earlier coursework. From protein thermodynamics, we know that proteins occupy ensembles of conformations. From enzyme kinetics, we know that catalytic rates depend on substrate availability and competing reactions. From physiology, we know that local changes participate in organism-wide feedback loops. Receptor biology combines these ideas: ligand binding changes a conformational ensemble, which changes reaction rates, which changes a cell’s behavior, which may change the concentration of the original ligand.
Working principle: A ligand does not dictate a response by itself. It changes the probabilities of molecular events in a system that already has structure, energy flow, and history.
Three distinctions should remain visible throughout the course:
- Recognition: How strongly and selectively does the ligand bind?
- Transduction: Which receptor states and downstream reactions does binding favor?
- Outcome: What does this particular cell or organism do with those reactions?
Confusing these levels creates familiar errors: assuming that the tightest binder must be the strongest agonist, that equal cAMP responses imply equal therapeutic effects, or that a receptor’s presence guarantees a functional response.
2. Receptor Families: Different Ways to Connect Recognition to Action
The major receptor families differ in how the initial binding event is coupled to an effector. Their architectures help explain their characteristic response times, although no family is confined to a single timescale. [Alberts et al., 2022; Berg et al., 2019]
- G protein–coupled receptors, or GPCRs: seven-transmembrane proteins that promote nucleotide exchange on heterotrimeric G proteins. Their outputs include second-messenger production, ion-channel regulation, trafficking, and transcription.
- Receptor tyrosine kinases, or RTKs: receptors with intrinsic tyrosine kinase activity. Ligand-induced rearrangement, often involving dimerization or reorientation of pre-existing dimers, promotes phosphorylation and recruitment of signaling proteins.
- Ligand-gated ion channels: receptors whose activation changes membrane conductance directly. Their immediate outputs depend on channel selectivity and electrochemical gradients.
- Nuclear receptors: intracellular, ligand-regulated transcription factors that commonly recognize lipophilic hormones or metabolites.
- Kinase-associated receptors: receptors such as cytokine receptors that lack intrinsic kinase activity but recruit kinases, notably JAK family proteins.
A ligand-gated channel is analogous to opening a gate in a dam: the stored electrochemical gradient supplies the immediate driving force. A GPCR is closer to activating a catalytic control system that changes the production of other signals. An RTK creates both catalytic activity and docking sites, assembling a molecular workspace. A nuclear receptor changes which genetic instructions are used.
A first messenger is the extracellular signal, such as GLP-1. A second messenger is an intracellular mediator such as cAMP, IP₃, DAG, or Ca²⁺. Second messengers differ physically: cAMP and IP₃ are soluble, DAG remains membrane-associated, and Ca²⁺ is heavily buffered and compartmentalized. These properties constrain where information can travel.
Amplification occurs when one activated component influences many downstream molecules. An activated receptor may activate multiple G proteins; an enzyme may synthesize many second-messenger molecules; a kinase may phosphorylate many substrates. However, amplification is not free. ATP supports phosphorylation and many transport processes; GTP supports the G protein cycle; ion pumps maintain gradients. These pathways operate away from equilibrium.
Nor is amplification unlimited. Enzyme saturation, phosphatases, phosphodiesterases, receptor desensitization, and substrate depletion constrain the output. The useful question is not simply “Does this pathway amplify?” but “Where does amplification occur, and where is it opposed?”
3. Affinity, Efficacy, Potency, and Receptor Reserve
Binding and response are different measurements
For a simple ligand–receptor interaction at equilibrium:
R + L ⇌ RL K_D = [R][L]/[RL] = k_off/k_on Fractional occupancy, θ = [L]/(K_D + [L])
The final expression assumes a single population of independent binding sites and uses the free ligand concentration. At [L] = KD, half the receptors are occupied. KD describes affinity, not the response produced by those occupied receptors.
A functional concentration–response curve is often described empirically by:
E = E_baseline + (E_max − E_baseline)
× [A]^nH/(EC₅₀^nH + [A]^nH)
- EC₅₀: agonist concentration producing half the fitted response range in that assay.
- Emax: the observed upper response asymptote under those conditions.
- nH: the Hill slope, describing curve steepness.
A functional Hill slope greater than one does not automatically demonstrate cooperative ligand binding. Multistep transduction, feedback, population heterogeneity, and assay processing can alter the slope. Similarly, EC₅₀ is not generally KD. A cell may reach half-maximal response while only a small fraction of receptors is occupied. [Black and Leff, 1983]
The operational model makes receptor reserve explicit
For a simple operational model with transducer slope one and baseline subtracted:
E = E_m τ[A] / {K_A + (1 + τ)[A]}
E_max,agonist = E_m τ/(1 + τ)
EC₅₀ = K_A/(1 + τ)
Here, Em is the system’s response capacity, KA is an agonist affinity parameter in the model, and τ describes operational efficacy: how effectively receptor occupancy drives that system. Some course treatments label an affinity-like parameter Ke; its definition must be checked rather than assumed equivalent to a directly measured KD.
Crucially, τ is not solely a molecular property of the agonist. It incorporates receptor abundance and coupling efficiency. A partial agonist in one cell may appear fully efficacious in another with greater receptor expression or stronger amplification. Functional fitting also does not necessarily identify affinity and efficacy independently with high precision.
Receptor reserve means that the available receptor population exceeds what is required to produce a specified, often near-maximal, response. It does not mean that some receptors are permanently assigned to an inactive “spare” category. With high reserve, reducing receptor numbers may initially shift the concentration–response curve rightward while leaving the maximal response nearly intact. Further receptor loss eventually reduces the maximum.
Equilibrium is not the whole pharmacological story
Two ligands can have similar affinity but different association and dissociation rates. In a simple binding model, residence time is approximately 1/koff. These kinetic differences matter when hormone exposure is pulsatile, extracellular concentrations change rapidly, or receptors internalize. Rebinding, membrane partitioning, and nonequilibrium exposure can further separate observed duration from a simple equilibrium prediction.
Whenever I compare agonists, I should ask: potency for which response, in which cells, at what receptor density, after how much time?
4. GPCR Activation: A Conformational Ensemble, Not a Binary Switch
GPCRs share a seven-transmembrane architecture but differ substantially in extracellular organization, ligand recognition, and activation mechanisms. Class A includes rhodopsin-like receptors, melanocortin receptors, and GHSR1a. Class B1 includes the secretin-family peptide receptors GLP-1R, GIPR, GCGR, and GHRHR. Class C includes metabotropic glutamate receptors and often uses large extracellular ligand-binding domains and dimeric architectures.
A useful minimal representation is:
R_inactive ⇌ R_intermediate ⇌ R_active Agonist binding changes the relative free energies and populations of these conformational states.
This connects directly to protein folding and allostery. A receptor is not a rigid lock waiting for a key. It is a fluctuating protein whose ligand-binding region is energetically coupled to its intracellular surface. Agonists favor ensembles that can engage transducers productively. Antagonists block agonist action without necessarily reducing basal activity; inverse agonists favor states with lower constitutive signaling.
In many GPCR activation structures, the intracellular end of transmembrane helix 6 moves outward, helping create a binding cavity for the G protein. Class A motifs such as DRY and NPxxY participate in conserved activation networks. These exact sequence motifs should not be treated as universal GPCR features: class B receptors use different conserved networks within a related overall architecture.
The C-terminal α5 helix of Gα inserts into the activated receptor’s intracellular cavity. Contacts with this helix, other G protein regions, intracellular loops, and the transmembrane core influence coupling. Selectivity is therefore not controlled by one simple “Gs-binding sequence.” It emerges from structural complementarity, dynamics, expression, and cellular organization.
An orthosteric ligand occupies the principal endogenous-ligand binding region. An allosteric ligand binds elsewhere and changes affinity, efficacy, or both. For peptide receptors, the orthosteric recognition surface can extend across an extracellular domain and the transmembrane bundle. “Binding site” may therefore mean a distributed interaction surface rather than a compact pocket.
A cryo-EM structure can reveal a highly informative receptor–ligand–G protein state, but it is not a complete movie of activation. Stabilizing constructs, transducer binding, membrane composition, and experimental preparation influence which states are captured. Structural snapshots become most powerful when integrated with kinetics, mutagenesis, spectroscopy, and functional measurements. [Alberts et al., 2022]
5. The G Protein Cycle and Its Four Major Output Families
Heterotrimeric G proteins contain Gα, Gβ, and Gγ. In the resting cycle, Gα binds GDP and associates with Gβγ. An activated receptor functions as a guanine nucleotide exchange factor: it promotes GDP release, permitting GTP binding. The receptor does not phosphorylate GDP into GTP.
1. Agonist binds and stabilizes an active receptor ensemble. 2. Receptor engages Gαβγ and promotes GDP release. 3. GTP binds Gα. 4. Gα–GTP and Gβγ regulate effectors. 5. Gα hydrolyzes GTP → GDP + Pi. 6. The inactive heterotrimer is re-established.
Textbook diagrams often depict complete separation of Gα and Gβγ. Depending on the G protein and experimental setting, activation may involve separation or rearrangement sufficient to permit effector engagement. Both Gα and Gβγ carry information. Regulators of G protein signaling, or RGS proteins, accelerate GTP hydrolysis for many Gα proteins and thereby shorten signaling.
- Gαs: stimulates susceptible adenylyl cyclases, increasing cAMP.
- Gαi/o: inhibits susceptible adenylyl cyclases; associated Gβγ can regulate GIRK potassium channels, calcium channels, and other effectors.
- Gαq/11: activates PLCβ, which cleaves PIP₂ into IP₃ and DAG.
- Gα12/13: activates Rho-directed guanine nucleotide exchange factors, influencing RhoA, cytoskeletal organization, contractility, and migration.
Gαs → adenylyl cyclase → ATP converted to cAMP Gαq/11 → PLCβ PIP₂ → IP₃ + DAG Gα12/13 → RhoGEF → RhoA–GTP → cytoskeletal effectors
Opioid and α₂-adrenergic receptors illustrate Gi/o-linked regulation. Their effects cannot be reduced to “less cAMP”: Gβγ-mediated regulation of ion channels can strongly influence neuronal excitability and neurotransmitter release.
GLP-1R primarily activates Gs, raising β-cell cAMP. However, cAMP is not simply an independent command to release insulin. It potentiates secretion in the context of glucose metabolism, electrical activity, calcium entry, and the exocytotic machinery. This helps explain why incretin-stimulated insulin secretion is substantially glucose-dependent. Receptor coupling outside the dominant Gs pathway can occur, but its importance must be established in the relevant physiological setting. [Drucker, 2018]
The beautiful feature of the G protein cycle is that timing is encoded chemically. GDP/GTP exchange initiates a signaling interval; hydrolysis terminates it. Receptor activity, nucleotide exchange, effector engagement, and GTPase acceleration together determine the duration of that interval.
6. cAMP Signaling: Local Information, PKA, EPAC, and Measurement
cAMP concentration reflects the balance between synthesis by adenylyl cyclases and hydrolysis by phosphodiesterases, or PDEs:
d[cAMP]/dt = v_adenylyl_cyclase − v_PDE Simple local approximation: d[cAMP]/dt = v_synthesis − k_degradation[cAMP]
Under the second approximation, the steady state is vsynthesis/kdegradation. Thus, increased cAMP can result from increased synthesis, reduced degradation, or both. An agonist and a PDE inhibitor may yield similar bulk cAMP concentrations while producing different spatial and temporal signals.
PKA: one messenger, many anchored targets
The classical PKA holoenzyme contains two regulatory and two catalytic subunits. cAMP binding to regulatory subunits relieves catalytic inhibition; the standard model involves release of active catalytic subunits, although cellular complexes can show more constrained or locally organized behavior than a simple freely diffusing picture suggests.
Type I and type II PKA contain different regulatory subunit classes. A-kinase anchoring proteins, or AKAPs, position PKA near selected substrates and often near PDEs, phosphatases, and other signaling proteins. This explains how a broadly used second messenger can generate specific responses.
- Metabolic targets: phosphorylase kinase and other regulators of glycogen metabolism.
- Cardiac targets: proteins involved in calcium entry, calcium reuptake, and contraction.
- Nuclear targets: CREB and associated transcriptional machinery.
The appropriate analogy is not a cell flooded uniformly with a broadcast signal. It is a building with local communication zones, strategically positioned receivers, and signal-removing barriers. Diffusion connects the zones, but geometry, buffering, and localized degradation prevent complete equivalence.
EPAC: cAMP without PKA
EPAC proteins are exchange factors directly activated by cAMP. They activate Rap-family small GTPases, including Rap1, and can regulate adhesion, integrin function, and secretion. EPAC2 is especially relevant to β-cell secretory signaling. Therefore, a cAMP-dependent response is not automatically PKA-dependent. [Berg et al., 2019; Drucker, 2018]
What a cAMP assay actually measures
Competitive HTRF cAMP assays use time-resolved fluorescence energy transfer to report cAMP through competition with a labeled reagent; in common formats, increased cellular cAMP decreases the relevant transfer signal. The assay-specific calibration, not intuition about fluorescence intensity, determines the concentration.
FRET sensors, including Epac-based constructs, report changes in distance or orientation between fluorophores as the sensor changes conformation. BRET sensors use a bioluminescent donor and avoid external excitation. Targeting sensors to membranes, cytosol, or endosomes can reveal signals hidden by whole-cell averages.
Every assay has limitations: sensor affinity, dynamic range, expression-induced buffering, temporal resolution, and possible perturbation of the pathway. PDE inhibition can make responses easier to detect but also changes the biology. A measurement is always the output of both the cell and the measurement system.
7. GRKs, β-Arrestins, Biased Agonism, and Receptor Trafficking
Desensitization changes the receptor’s working relationships
Activated GPCRs can be phosphorylated by G protein–coupled receptor kinases, or GRKs, on intracellular serine and threonine residues, often in the C-terminal tail and sometimes intracellular loops. β-Arrestins recognize combinations of receptor activation and phosphorylation, limiting further G protein coupling and connecting receptors to trafficking machinery.
β-Arrestins can bind clathrin and AP2, supporting receptor entry into clathrin-coated pits. They also scaffold signaling proteins, including components associated with ERK, Src, and PI3K pathways. However, the statement “β-arrestin activates ERK independently of G proteins” is not universally valid. Apparent arrestin-dependent outputs may still require upstream G protein activity, vary with receptor and cell type, or reflect arrestin-mediated termination of another signal.
This is a lesson in causal inference: recruitment, necessity, and sufficiency are different claims. Observing arrestin recruitment does not establish that arrestin caused a measured downstream response.
Biased agonism is a comparative, system-aware concept
Different ligands can favor receptor ensembles with different relative capacities to activate G proteins, recruit arrestins, or engage other processes. This is ligand bias. Yet assay amplification, receptor reserve, exposure time, and receptor abundance can create apparent differences even without a ligand-specific change in pathway preference.
A commonly used operational comparison is:
Transduction coefficient for pathway p: log₁₀(τ/K_A)_p Δlog(τ/K_A)_p = test ligand value − reference ligand value ΔΔlog(τ/K_A) = Δlog(τ/K_A)_pathway 1 − Δlog(τ/K_A)_pathway 2 Bias factor = 10^[ΔΔlog(τ/K_A)]
The sign depends on pathway ordering. The estimate requires suitable data and model assumptions; it becomes uncertain when curves are incomplete or parameters are poorly identified. “Biased” should therefore always imply relative to a reference ligand, between specified responses, under specified conditions.
For GLP-1R, agonists with altered arrestin recruitment and trafficking can produce prolonged signaling or improved insulin secretion in experimental systems. But less arrestin recruitment does not automatically mean a better drug. Pharmacokinetics, receptor recycling, endosomal signaling, tolerability, and tissue distribution all contribute. [Jones et al., 2018]
Internalization is a change of location, not necessarily an off switch
After endocytosis, receptors enter early endosomal sorting systems. They may recycle to the surface or proceed toward lysosomal degradation. Recycling can restore responsiveness; degradation can produce longer-lasting downregulation. Some GPCRs continue signaling from endosomes, so internalization can reshape rather than simply terminate information flow. [Irannejad et al., 2013]
Surface receptor
↓ activation and internalization
Early endosomal sorting
↙ ↘
Recycling pathways Late endosome/lysosome
↓ ↓
Surface recovery Receptor degradation
Comparisons among exendin-4, liraglutide, and semaglutide require matched conditions. Ligand residence, receptor occupancy, acylation, albumin binding, endosomal dissociation, and assay timing can influence apparent internalization and recycling. A single universal ranking is unlikely to transfer across all systems.
Tachyphylaxis means rapidly diminishing responsiveness during repeated or sustained stimulation. It is not synonymous with receptor degradation. Rapid uncoupling, depleted releasable pools, altered neural circuits, and physiological counter-regulation may all contribute. For GLP-1-based therapy, adaptation of gastric-emptying effects need not imply equivalent loss of insulinotropic or appetite effects. [Drucker, 2018]
8. Class B Peptide Receptors: GLP-1R, GIPR, GCGR, and Coagonism
Class B1 peptide receptors provide an especially clear connection between peptide structure and receptor activation. A useful model divides recognition between a large extracellular domain and the membrane-embedded receptor core.
- The peptide’s C-terminal region often makes important affinity-generating contacts with the extracellular domain.
- The peptide’s N-terminal region engages the transmembrane core and extracellular loops, favoring activation.
The membrane-proximal activation region is sometimes called the J-domain, or juxtamembrane domain, in this two-domain framework. The model is useful but not absolute: binding and activation are cooperative, and both receptor regions contribute to the final complex.
This explains why a peptide fragment may retain binding while losing agonism. Binding energy distributed across one region can remain, while the contacts needed to stabilize an active receptor ensemble disappear. Cryo-EM structures help locate these contacts, but mutagenesis and functional experiments are needed to determine their energetic and pharmacological importance.
Related receptors do not imply interchangeable physiology
- GLP-1R: promotes glucose-dependent insulin secretion and participates in glucagon regulation, gastric function, and neural control of intake.
- GIPR: mediates insulinotropic signaling and has additional tissue- and state-dependent metabolic actions.
- GCGR: has major hepatic actions supporting glucose production and contributes to amino acid metabolism and broader energy balance.
All three commonly engage Gs, yet their physiological effects differ because receptor distribution, downstream machinery, and whole-body feedback differ. “Raises cAMP” is a molecular description, not a complete physiological explanation.
Receptor selectivity depends on distributed contacts, including peptide side chains, backbone geometry, receptor extracellular loops, and the extracellular domain. A substitution can alter both affinity and the activation geometry of the bound complex. Consequently, receptor activity ratios must be measured rather than inferred from sequence similarity.
Why combine pathways that seem to oppose each other?
Tirzepatide is a dual GIPR/GLP-1R agonist. Retatrutide is a triple GIPR/GLP-1R/GCGR agonist. The counterintuitive element is glucagon receptor agonism in a metabolic treatment: glucagon can increase hepatic glucose output, yet appropriately balanced coagonism may combine incretin-supported glycemic control with effects on energy balance and other metabolic processes.
The outcome depends on integrated receptor engagement, not simply the label “dual” or “triple.” Effective balance involves free exposure, receptor abundance, functional potency, efficacy, tissue access, and duration. A ratio measured in overexpressing cell lines is not automatically the engagement ratio in human liver, pancreas, or brain.
The phase 2 retatrutide trial in people with type 2 diabetes provides clinical evidence for metabolic efficacy, but the clinical response does not by itself quantify each receptor’s contribution. Mechanistic attribution requires complementary experiments and appropriate comparators. [Drucker, 2018; Rosenstock et al., 2023]
9. Melanocortin Receptors: Shared Peptide Origins, Distinct Physiological Roles
The melanocortin system illustrates how proteolytic processing creates several messages from one precursor. Proopiomelanocortin, or POMC, undergoes tissue-dependent cleavage and modification to yield peptides including ACTH and α-, β-, and γ-MSH. Products depend on the available processing enzymes and can differ across species. Not every POMC-expressing cell releases the same peptide mixture.
Melanocortin peptides share recognition features, notably the His-Phe-Arg-Trp sequence within their pharmacophores, but surrounding residues, modifications, and conformations influence receptor preferences. A shared motif supplies a foundation for recognition, not a guarantee of equal receptor activity.
- MC1R: prominent in melanocytes; promotes melanogenic signaling and influences eumelanin production. It also has functions beyond pigmentation.
- MC2R: the ACTH receptor in the adrenal cortex; requires the accessory protein MRAP for normal functional expression and signaling.
- MC3R: participates in energy homeostasis and adaptation to nutritional state; peripheral melanocortin biology also implicates it in inflammatory regulation.
- MC4R: central to appetite and energy-balance circuits; impaired signaling can cause severe obesity.
- MC5R: contributes to exocrine and other peripheral functions, including aspects of sebaceous gland biology.
These receptors predominantly connect to Gs/cAMP signaling, but their actions cannot be understood from cAMP alone. Accessory proteins, constitutive activity, cell type, and alternative effectors matter.
At MC4R, α-MSH promotes activation. Agouti-related peptide, or AgRP, opposes melanocortin signaling and can function as an inverse agonist in appropriate assays by reducing constitutive activity. This is more than blocking a competing agonist: an inverse agonist can lower signaling below the ligand-free baseline.
Neutral antagonist: blocks agonist action without necessarily changing basal activity Inverse agonist: reduces constitutive receptor signaling Agonist: increases receptor-mediated signaling above basal activity
AgRP neurons also release NPY and GABA. Their rapid effects on feeding cannot all be attributed to AgRP binding MC4R. This distinction between a neuron’s identity and the actions of one of its transmitters is essential.
For peptide design, melanocortin receptors present a selectivity challenge: an appetite-directed agonist should not be assumed free of pigmentation, autonomic, or other effects merely because it contains a recognizable melanocortin motif. MC3R is also not simply a weaker version of MC4R; its context-dependent roles require separate mechanistic study.
10. Ghrelin, GHSR1a, GHRH Analogs, and Pulsatile Endocrine Signaling
Ghrelin is unusual because acylation is central to its canonical receptor activity. Attachment of an octanoyl group to Ser3 by ghrelin O-acyltransferase supports activation of GHSR1a. This is a vivid reminder from peptide chemistry that a small covalent modification can change biological identity.
GHSR1a is a class A GPCR with prominent Gq/11-linked signaling and unusually high constitutive activity in many experimental systems. Ghrelin participates in appetite regulation and stimulates growth hormone secretion. Constitutive activity means that ligand-free receptors already occupy signaling-competent states to a meaningful extent; it makes the distinction between antagonism and inverse agonism particularly important.
Synthetic growth hormone secretagogues such as GHRP-6, GHRP-2, and ipamorelin demonstrate that small peptides can reproduce receptor activation without copying the entire endogenous hormone. D-amino acids, noncanonical aromatic residues, and selected charged groups alter conformation, proteolytic stability, and receptor interactions. Selectivity must include both receptor-level behavior and downstream endocrine responses; activity at GHSR does not establish an identical cortisol, prolactin, or GH profile across compounds.
GHSR and GHRHR are different receptors
GHRH analogs act at the growth hormone–releasing hormone receptor, a class B GPCR primarily coupled to Gs. CJC-1295 is therefore not a ghrelin-receptor agonist. The long-acting, drug-affinity-complex version of CJC-1295 uses a maleimide-containing modification designed to react with circulating albumin thiols, particularly the free cysteine at albumin Cys34. Albumin conjugation prolongs exposure.
The name “CJC-1295 without DAC” is used inconsistently outside formal pharmacology and often refers to a shorter-acting modified GHRH peptide. It should not be assumed chemically or pharmacokinetically equivalent to albumin-conjugating CJC-1295.
GH release is pulsatile because pituitary responsiveness is embedded in hypothalamic GHRH and somatostatin regulation, sleep-related inputs, nutritional signals, and feedback. GH then acts through a cytokine-receptor/JAK2–STAT pathway and promotes IGF-1 production, prominently in the liver but also in other tissues.
Ghrelin → GHSR1a → predominantly Gq/11-linked signaling GHRH → GHRHR → predominantly Gs/cAMP signaling Both can influence pituitary GH release. GH → GH receptor → JAK2/STAT signaling → IGF-1 and other responses
A longer-lived peptide does not simply create “more physiological signaling.” It changes the temporal input. A sustained stimulus can be interpreted differently from repeated pulses because receptors, feedback circuits, and transcriptional systems adapt. Body-composition changes must also be separated into fat mass, lean tissue, and fluid effects rather than interpreted as a single direct measure of muscle growth.
11. MAPK, PI3K–Akt, and mTOR: Signaling as Regulated Protein Assembly
RTKs generate phosphorylated docking sites that recruit proteins with domains such as SH2 or PTB domains. These interactions assemble signaling complexes and position enzymes beside substrates. Specificity therefore depends not only on catalytic recognition but also on who is brought near whom.
The RAS–RAF–MEK–ERK pathway
Activated RTK → adaptor proteins → SOS
SOS promotes:
RAS–GDP → RAS–GTP
RAS–GTP → RAF → MEK1/2 → ERK1/2
↓
cytoplasmic and nuclear targets
SOS is a guanine nucleotide exchange factor for RAS. RAS is a small GTPase, distinct from heterotrimeric Gα. RAF is a kinase; MEK is a dual-specificity kinase that activates ERK through phosphorylation of threonine and tyrosine in its activation loop. ERK then regulates many substrates.
GPCRs can reach ERK through several routes, including G protein effectors, Src-family kinases, receptor transactivation, and scaffolding mechanisms. Thus, increased phospho-ERK is a convergent readout, not proof of one upstream route.
Transient and sustained ERK signals can produce different outcomes because targets differ in activation thresholds, localization, and turnover. Feedback from ERK to upstream components can shorten or reshape the response. The time course may carry as much information as the peak.
PI3K–Akt: a lipid becomes a recruitment platform
Class I PI3K: PI(4,5)P₂ → PI(3,4,5)P₃ PIP₃ recruits proteins with suitable lipid-binding domains, including Akt and PDK1. PDK1 → Akt Thr308 phosphorylation mTORC2 → Akt Ser473 phosphorylation
Class IA PI3Ks include p110α, p110β, and p110δ catalytic isoforms; class IB includes p110γ. Their regulation and expression differ. RTKs often recruit class IA signaling, whereas GPCR inputs prominently involve p110γ and, in some settings, p110β.
PIP₃ does not directly “turn into Akt activity.” It helps recruit and organize the proteins needed for activation. PTEN opposes the pathway by removing the 3-phosphate from PIP₃. Akt affects survival, metabolism, and growth through multiple substrates.
mTOR integrates growth signals with resource availability
mTORC1 responds to growth-factor signaling, amino acid availability, energy state, and stress. Akt can relieve TSC-mediated inhibition of Rheb, while nutrient-sensitive machinery regulates mTORC1 localization and access to activation. mTORC1 phosphorylates S6K1 and 4E-BP proteins, affecting translation and growth. mTORC2 has distinct composition and functions, including regulation of Akt and cytoskeletal pathways.
GLP-1R-linked PI3K–Akt signaling has been associated with β-cell survival and proliferative responses in experimental models. Translation requires caution: adult human β-cells have a more restricted proliferative capacity than many rodent or transformed-cell systems. [Drucker, 2018]
Manning and colleagues’ catalog of the human kinome underscores both the diversity of kinase regulation and the challenge of drug selectivity among related catalytic domains. Kinases share chemistry but differ in regulation, localization, interaction partners, and biological role. [Manning et al., 2002]
12. Calcium and Transcription: Integrating Fast Signals into Longer-Term Responses
Calcium is a controlled gradient, not merely a concentration
Cytosolic free Ca²⁺ is normally kept far below extracellular and endoplasmic-reticulum concentrations. Channels permit rapid increases; pumps and exchangers restore gradients. Because excessive or prolonged cytosolic Ca²⁺ is harmful, calcium signaling depends on spatially and temporally restricted changes.
Gq/11 → PLCβ → IP₃ IP₃ + IP₃ receptor → ER Ca²⁺ release SERCA: ATP-dependent transport of cytosolic Ca²⁺ back into the ER ER Ca²⁺ depletion → STIM1 activation STIM1 → Orai1 channel activation → store-operated Ca²⁺ entry
STIM1 senses ER luminal calcium and accumulates at ER–plasma-membrane junctions when stores are depleted. There it promotes opening of Orai channels. Store-operated calcium entry helps replenish stores and supports sustained signaling.
DAG and calcium also connect PLC signaling to conventional PKC isoforms. Novel PKCs respond to DAG without requiring calcium in the same way, whereas atypical PKCs have different regulatory requirements. “PKC activation” therefore needs an isoform context.
Calmodulin binds calcium and changes its interactions with target proteins. CaMKII can undergo autophosphorylation that preserves activity beyond an individual calcium pulse, creating a biochemical mechanism for short-term memory and frequency sensitivity.
β-cell secretion is an integration problem
Glucose metabolism increases ATP/ADP
↓
ATP-sensitive K⁺ channels close
↓
Membrane depolarization
↓
Voltage-gated Ca²⁺ channels open
↓
Ca²⁺-triggered insulin granule fusion
GLP-1R → cAMP → PKA and EPAC
↓
Modulation of electrical, Ca²⁺, and exocytotic processes
This is why calcium and cAMP should not be learned as isolated pathways. Calcium provides a central trigger for granule fusion; cAMP changes the effectiveness and organization of the secretion machinery. Oscillation frequency, amplitude, and coordination influence the integrated output. [Drucker, 2018]
CREB, nuclear receptors, and STATs are distinct transcriptional systems
PKA can phosphorylate CREB, notably at Ser133, promoting interactions with coactivators such as CBP/p300. However, CREB phosphorylation alone is not sufficient to predict transcription. CRTC coactivators, chromatin state, other transcription factors, and promoter context matter. A CRE sequence is part of a regulatory architecture, not an automatic cAMP switch.
Nuclear receptors instead contain characteristic DNA-binding and ligand-binding domains and respond directly to appropriate ligands, such as steroid hormones, thyroid hormone, retinoids, or metabolic ligands. Most peptide hormones do not enter cells to bind nuclear receptors. They influence transcription indirectly through membrane-initiated pathways.
STAT signaling follows another route:
Ligand binds kinase-associated receptor
↓
JAK activation and receptor phosphorylation
↓
STAT recruitment and phosphorylation
↓
STAT dimerization and nuclear accumulation
↓
Context-dependent transcription
Leptin, GH, and cytokines illustrate different uses of this general architecture. SOCS proteins and phosphatases provide feedback inhibition. GLP-1R signaling can influence β-cell gene programs supporting insulin production, differentiated function, and stress responses, but the genes observed depend on species, metabolic condition, and exposure duration. [Alberts et al., 2022; Drucker, 2018]
13. Appetite Regulation: Receptors Embedded in Neural and Endocrine Circuits
At the organismal level, signaling pathways become circuit components. The arcuate nucleus contains populations often described as anorexigenic POMC/CART neurons and orexigenic AgRP/NPY neurons. This is a useful starting map, not a complete division of the hypothalamus into an “off switch” and an “on switch” for eating.
POMC-derived melanocortins can activate MC4R on downstream neurons. AgRP neurons oppose melanocortin signaling through AgRP and also act through NPY and GABA. Nutrients, gastrointestinal signals, learned cues, circadian state, and other inputs alter these populations and their targets.
Leptin reports aspects of energy stores through the long receptor isoform LepRb, engaging JAK2–STAT3 and additional pathways. Its action can support reduced intake and altered energy expenditure. However, obesity often involves impaired leptin responsiveness rather than simple absence of leptin. Increasing ligand concentration does not necessarily repair impaired transport, receptor regulation, or downstream network responsiveness.
GLP-1 signaling involves peripheral sources and central preproglucagon neurons, notably in the nucleus tractus solitarius. GLP-1 receptors participate in hindbrain, hypothalamic, and reward-related networks. Endogenous gut-derived GLP-1, centrally released GLP-1, and long-acting therapeutic agonists do not necessarily reach the same receptors with the same timing.
For a peptide drug, brain action depends on vascular access, receptor location, accessible brain regions, neural relays, and molecular properties. It is too crude to say that a compound either “crosses the blood–brain barrier” or cannot influence appetite. Peripheral and accessible central targets can communicate with deeper circuits.
GLP-1 and melanocortin pathways can converge on energy-balance regulation without forming a single obligatory linear chain. Parallel circuits, downstream convergence, and feedback all matter. Reduced food intake may also involve changes in satiety, reward, nausea, or aversion; these outcomes should be distinguished experimentally rather than grouped as one appetite signal. [Drucker, 2018]
Receptor pharmacology asks what a molecule does at a receptor. Circuit pharmacology asks what happens when that receptor is changed in one part of an interacting nervous system.
14. Pharmacological Control: Allostery, Kinase Inhibition, Degradation, and Combinations
Allosteric modulators reshape an existing signal
A positive allosteric modulator, or PAM, increases some aspect of an orthosteric ligand’s action; a negative allosteric modulator, or NAM, decreases it. A modulator may alter binding affinity, signaling efficacy, or both. Some also possess intrinsic agonist activity.
A PAM can, in principle, preserve the timing and location of endogenous hormone release by amplifying a signal only where that hormone is present. This is not guaranteed: intrinsic agonism, strong cooperativity, or altered desensitization can change the pattern. Allosteric effects can also show probe dependence, meaning that the same modulator affects different orthosteric ligands differently.
Kinase inhibitors confront conserved chemistry
ATP-binding regions are conserved across many kinases, making off-target inhibition a recurring challenge. Selectivity can be improved by exploiting neighboring pockets, distinctive conformations, allosteric sites, or suitable reactive residues. Nevertheless, selectivity measured in a purified panel is not identical to selectivity in cells.
Cellular ATP concentration, permeability, protein binding, kinase activation state, and exposure influence inhibition. A phenotype produced by one inhibitor is therefore weak evidence for a unique causal target. Stronger inference combines chemically distinct inhibitors, genetics, rescue experiments, and direct target-engagement measurements. [Manning et al., 2002]
PROTACs remove the protein rather than merely block its activity
Target protein + PROTAC + E3 ubiquitin ligase
↓ productive ternary complex
Target ubiquitination
↓
Proteasomal degradation
A PROTAC connects a target-binding ligand to an E3-ligase-binding ligand. Productive geometry matters: strong binary binding does not guarantee efficient ubiquitination. At high concentrations, unproductive binary complexes can sometimes reduce ternary-complex formation, creating a hook effect.
Degradation can remove scaffolding functions as well as catalytic activity, so it need not phenocopy a kinase inhibitor. Its duration depends partly on protein resynthesis, not simply circulating drug concentration. Tissue-specific ligase expression, accessibility, permeability, and resistance mechanisms constrain the approach.
Combination therapy changes interacting control systems
Combining GLP-1R agonism with amylin signaling or leptin-related interventions aims to influence complementary components of energy regulation. Amylin receptors are complexes of the calcitonin receptor with receptor activity-modifying proteins, illustrating how an accessory protein changes pharmacological identity.
Combination benefits must be demonstrated, not presumed. Two anorectic signals may be additive, synergistic under a specified reference model, redundant, or limited by shared tolerability. Leptin resistance can constrain the value of additional leptin signaling. Clinical combination design therefore requires measurements of efficacy, adverse effects, exposure, and compensatory physiology—not just separate evidence that each component activates its receptor.
15. Connections to Peptide Chemistry: Designing the Message and Its Delivery
For Skipper, the key connection to peptide synthesis, folding, pharmacology, and delivery is that a therapeutic peptide is simultaneously a recognition surface, a conformational ensemble, a protease substrate, and a transported chemical species. Optimizing only one of these identities rarely produces the best medicine.
Sequence controls more than affinity
A residue substitution can change receptor contacts, helix propensity, local flexibility, charge distribution, proteolytic susceptibility, and solubility. At a class B receptor, changing an N-terminal activation contact may alter efficacy disproportionately to binding. Modifying a more extracellularly engaged region may alter affinity or selectivity while retaining activation competence.
This is why alanine scanning should be interpreted alongside structural and functional measurements. A loss of activity after mutation could reflect weaker binding, altered active-state stabilization, peptide misfolding, aggregation, or faster degradation. A potency shift alone does not distinguish these possibilities.
Protease resistance can alter signaling indirectly
D-amino acids, α-aminoisobutyric acid, N-methylation, terminal modifications, and cyclization can protect susceptible bonds or alter accessible conformations. GLP-1 analog design illustrates the importance of preventing rapid DPP-4 cleavage near the N-terminus. However, protecting the peptide can also change receptor interactions or exposure duration; “more stable” is not synonymous with “pharmacologically unchanged.”
Conformational restriction can lower the entropy cost of binding if the constrained structure resembles the bound state. But excessive restriction can prevent the adjustments needed for productive binding or activation. This is the same thermodynamic lesson encountered in protein engineering: preorganization helps only when it preorganizes the right ensemble.
Acylation changes exposure and molecular interactions
Lipidation, as used in liraglutide and semaglutide, promotes albumin association and prolongs exposure. Linker chemistry, attachment position, and lipid structure influence the balance among albumin binding, receptor accessibility, self-association, and distribution.
Total plasma concentration
= free concentration + protein-bound concentration
Receptor engagement depends on accessible ligand,
not simply the total amount measured in plasma.
Albumin binding acts as a dynamic reservoir, but it can lower the instantaneous free fraction. Consequently, an albumin-binding peptide may appear less potent in an albumin-containing assay while still producing prolonged activity in vivo. Assay composition belongs in the interpretation of structure–activity relationships.
Multiagonist design is a constrained optimization problem
A dual or triple agonist must satisfy several partially conflicting recognition surfaces while maintaining manufacturability, stability, solubility, and appropriate exposure. The objective is not maximal potency at every receptor. It is an appropriate pattern of receptor engagement in the organism.
A useful development sequence is:
- Establish identity, purity, integrity, and solution behavior.
- Measure binding and kinetic properties where feasible.
- Measure pathway responses over time at controlled receptor expression.
- Assess arrestin recruitment, internalization, recycling, and degradation.
- Test endogenous-receptor systems and relevant tissue contexts.
- Relate functional effects to free exposure and pharmacokinetics.
The central insight is that medicinal peptide chemistry does not merely improve how tightly a message binds. It can change which message is transmitted, where it is delivered, and how long the cell continues to interpret it.
16. Common Misconceptions and the Corrections Worth Remembering
- “EC₅₀ measures affinity.” EC₅₀ measures functional potency under particular conditions. Affinity, efficacy, receptor reserve, time, and assay architecture all influence it.
- “A full agonist is intrinsically full everywhere.” Observed maximal efficacy depends on the signaling system. Strong amplification can make a partial agonist appear full.
- “A steep Hill slope proves cooperative receptor binding.” Functional steepness can arise downstream of binding or from experimental and population-level effects.
- “A receptor activates only one pathway.” Dominant coupling is useful shorthand, but coupling, scaffolding, and downstream convergence are context-dependent.
- “The receptor converts GDP to GTP.” It promotes GDP release; GTP then binds from the cellular nucleotide pool.
- “β-Arrestin is either an off switch or an independent signaling pathway.” It regulates coupling, trafficking, and scaffolding; mechanistic independence requires experimental demonstration.
- “Internalized receptors are silent.” Some signal from endosomes. Internalization changes location, partners, and fate.
- “Biased agonism is a context-free property.” Bias is quantified relative to a reference ligand and specified pathways, with careful attention to system effects and kinetics.
- “Peptide hormones directly activate nuclear receptors.” Most act through membrane receptors and influence transcription indirectly. CREB, STATs, and nuclear receptors are distinct molecular systems.
- “A longer half-life always improves signaling.” It improves persistence, but may alter physiological pulses, adaptation, tissue exposure, and adverse effects.
- “The same second messenger means the same biological response.” cAMP in a hepatocyte, β-cell, and neuron is interpreted by different molecular and physiological networks.
- “A clinical response proves the proposed molecular mechanism.” It demonstrates an outcome under trial conditions. Attribution to particular receptors, pathways, or signaling biases requires additional evidence.
Final organizing question: For every signaling result, identify the ligand, receptor state, transducer, compartment, timescale, cellular context, and measured output. If one of these is missing, the interpretation is probably incomplete.
Sources and Further Reading
The assigned textbooks provide the broad cellular and biochemical framework. The primary papers below support specific pharmacological, trafficking, genomic, and clinical examples; clinical efficacy should not be treated as independent proof of every proposed cellular mechanism.
- Alberts, B., et al. Molecular Biology of the Cell, 7th ed. 2022.
- Berg, J. M., Tymoczko, J. L., Gatto, G. J., Jr., and Stryer, L. Biochemistry, 9th ed. 2019.
- Bhattacharya, J. S., and Bhattacharya, D. J. Cell Signaling, 4th ed. Course-listed companion text.
- Black, J. W., and Leff, P. “Operational Models of Pharmacological Agonism.” Proceedings of the Royal Society of London B, 1983.
- Drucker, D. J. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell Metabolism, 2018. DOI: 10.1016/j.cmet.2018.03.001.
- Manning, G., et al. “The Protein Kinase Complement of the Human Genome.” Science, 2002. DOI: 10.1126/science.1075762.
- Rosenstock, J., et al. “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial.” The Lancet, 2023. DOI: 10.1016/S0140-6736(23)01053-X.
- Jones, B., et al. “Targeting GLP-1 Receptor Trafficking to Improve Agonist Efficacy.” Nature Communications, 2018, 9:1602. DOI: 10.1038/s41467-018-03941-2.
- Irannejad, R., et al. “Conformational Biosensors Reveal GPCR Signalling from Endosomes.” Nature, 2013, 495:534–538. DOI: 10.1038/nature12000.